Emergent BioSolutions (EBS) Misses Q2 EPS by $1.21
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $7.96 +1.40%
Revenue Growth %: +32.0%
Financial Fact:
Selling, general and administrative: 40.69M
Today's EPS Names:
MAYS, CRMT, REPL, More
Revenue Growth %: +32.0%
Financial Fact:
Selling, general and administrative: 40.69M
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q2 EPS of $0.33, $1.21 worse than the analyst estimate of $1.54. Revenue for the quarter came in at $397.5 million versus the consensus estimate of $398.93 million.
GUIDANCE:
Emergent BioSolutions sees Q3 2021 revenue of $1700-1900 billion, versus the consensus of $1.8 billion.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
- UBS Reiterates Buy Rating on General Motors (GM) as Defense Opportunity in Focus
- Worthington Enterprises raises dividend 5%, adds board member
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
